ConductScience.org, home

Paper24656178

Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy.

Scheffer HJ and 9 others. J Vasc Interv Radiol, 2014. Cited by 302 papers, by iCite.

Cite this record

ConductScience Library. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. Papers, record 24656178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24656178

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy.
PubMed
Journal
J Vasc Interv Radiol
PubMed
Year
2014
PubMed
Publication types
Journal Article, Systematic Review
PubMed
Citations, by iCite
302
iCite
Relative citation ratio, by iCite
11.8
iCite
Revised in PubMed
2025-07-28
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Scheffer HJHester J
2Nielsen KKarin
3de Jong MCMarcus C
4van Tilborg AAAukje A J M
5Vieveen JMJenny M
6Bouwman ARArthur R A
7Meijer SSybren
8van Kuijk CCornelis
9van den Tol PMPetrousjka M P
10Meijerink MRMartijn R

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ablation TechniquesMajor topic
ElectrochemotherapyMajor topic
NeoplasmsMajor topic
Diffusion Magnetic Resonance Imaging
Humans
Multimodal Imaging
Positron-Emission Tomography
Postoperative Complications
Predictive Value of Tests
Risk Factors
Time Factors
Tomography, X-Ray Computed
Treatment Outcome

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT04276857Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic CancerBackgroundClinicalTrials.gov
NCT07782164Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)BackgroundClinicalTrials.gov

Download CSV of trials

Cited by175

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 302 citations.

PMIDTitleJournalYearIn PapersSource
42905914Biophysical principles of pulsed field ablation.Europace2026https://conductscience.org/library/papers/42905914PubMed
42824129Compound steep-pulse irreversible electroporation for prostate ablation in Beagle dogs: parameter evaluation and short-term safety.Front Urol2026https://conductscience.org/library/papers/42824129PubMed
42779964Case Report: Late repeat pancreatic irreversible electroporation in the long-term multidisciplinary management of unresectable pancreatic ductal adenocarcinoma.Front Oncol2026https://conductscience.org/library/papers/42779964PubMed
42778637Irreversible Electroporation for Colorectal Liver Metastases: Long-term Outcomes from a Transatlantic Multicenter Study.Cardiovasc Intervent Radiol2026https://conductscience.org/library/papers/42778637PubMed
42688057Does tumor location affect irreversible electroporation outcomes in pancreatic cancer? A head-to-head comparative cohort study.Front Oncol2026https://conductscience.org/library/papers/42688057PubMed
42637830Safety and Efficacy of an Irreversible Electroporation System with Real-Time Electrical and Thermal Monitoring for Liver Tumors: A Bicentric Retrospective Study.Cardiovasc Intervent Radiol2026https://conductscience.org/library/papers/42637830PubMed
42627535Incidence and risk factors of complications following microsecond and nanosecond pulsed electric field ablation for hepatocellular carcinoma: a 10-year multicenter cohort study.Eur Radiol2026https://conductscience.org/library/papers/42627535PubMed
42614700Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications.Biomater Res2026https://conductscience.org/library/papers/42614700PubMed
42504355Irreversible Electroporation Versus Radiofrequency Ablation for Hepatic Malignancies: A Systematic Review and Meta-Analysis.Cureus2026https://conductscience.org/library/papers/42504355PubMed
42382132Efficacy and safety of multiple treatments for small hepatocellular carcinoma: an updated systematic review and component network meta analysis.EClinicalMedicine2026https://conductscience.org/library/papers/42382132PubMed
42369083Biomimetic Nanogels Programmed for Irreversible-Electroporation-Primed Tumor Microenvironments to Elicit Durable Antitumor Immunity.Biomater Res2026https://conductscience.org/library/papers/42369083PubMed
42018500High-intensity irreversible electroporation targeting intracellular structures enhance tumor ablation in lung cancer models.PLoS One2026https://conductscience.org/library/papers/42018500PubMed
41908232Irreversible electroporation for localized prostate cancer: risk-stratified oncologic outcomes and functional preservation.Prostate Int2026https://conductscience.org/library/papers/41908232PubMed
41729480Stereotactic two-needle irreversible electroporation of liver tumors near critical structures: a proof-of-concept study.Eur Radiol Exp2026https://conductscience.org/library/papers/41729480PubMed
41295487In Situ Vaccination by Tumor Ablation: Principles and Prospects for Systemic Antitumor Immunity.Vaccines (Basel)2025https://conductscience.org/library/papers/41295487PubMed
41070061Application of a new coaxial bipolar electrode for the treatment of vertebral metastases: a pilot study in an ovine model.Front Med (Lausanne)2025https://conductscience.org/library/papers/41070061PubMed
40851065Real-world safety of irreversible electroporation therapy for tumors with nanoknife: MAUDE database analysis.BMC Surg2025https://conductscience.org/library/papers/40851065PubMed
40794619Management of liver metastases from uveal melanoma.Br J Surg2025https://conductscience.org/library/papers/40794619PubMed
40674565Electrical Stimulation of Cells: Drivers, Technology, and Effects.Chem Rev2025https://conductscience.org/library/papers/40674565PubMed
40630200Evaluating the immune response in a murine cancer model between irreversible electroporation and an advanced biphasic pulsed electric field technology.Front Oncol2025https://conductscience.org/library/papers/40630200PubMed

See all 175 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24656178

GET https://conductscience.org/api/papers/v1/24656178/cited_by?page=2